Apollo Global in talks to acquire J&J orthopedics unit, terms undisclosed
Apollo Global is in talks to acquire Johnson & Johnson’s orthopedics unit, Bloomberg News reports. The potential deal would test Apollo’s ability to deploy capital into a healthcare asset while adding transaction and execution risk before terms are known.
STOCK PHOTO · MAURÍCIO MASCAROThe story
Apollo Global is in talks to acquire an orthopedics unit from Johnson & Johnson. The talks follow J&J's broader effort to focus its portfolio, but it remains unclear whether the discussions are exclusive or advanced. No signed agreement or commitment to transact has been announced, so the situation remains subject to negotiations and potential approval requirements.
For Apollo Global, the direct mechanism is capital deployment into a healthcare business that could generate future fee or investment income, depending on the transaction structure. For J&J, a sale would potentially simplify the portfolio and provide proceeds, but details on how the unit contributes to current revenue or earnings are limited.
Key uncertainties include the purchase price, financing structure, valuation, expected closing date and the specific assets included in the unit. Apollo's FY2025 revenue was $32.0B, up 22.7% year over year, with a 10.6% net margin and $5.54 diluted EPS; those figures provide scale but do not quantify the effect of this potential acquisition.
The next useful milestones are confirmation of a signed agreement, disclosure of the assets and price, and Apollo's next earnings update for any effect on deployment, financing or fee-related earnings. J&J's comments on proceeds and portfolio strategy would also clarify the seller's rationale.
Our read · Fri, Sep 11
APO faces a mixed setup: the J&J orthopedics talks could add a new healthcare deployment opportunity, but absent terms the transaction and execution risks remain unpriced.
Why. The implication for APO turns on deal quality rather than the headline alone: a signed transaction at attractive terms could expand capital deployment, while an expensive or heavily financed purchase could dilute the benefit. With no price, structure, assets or closing timetable reported, the evidence does not support a directional equity call.
Both cases
What could change this view: The talks could end without a transaction, or disclosed terms could show an unattractive price, financing burden or limited earnings contribution.
Who reported it · 1
Keep reading
More on APO
Hackers breach Apollo Global as alternative-asset manager's AUM hits $1 trillionLatest on the Wire
Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →Latest on the Wire
Anthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeBeijing plans to bar young red-chip firms from overseas listingsGerman producer prices jump 8.1% in October as industrial inflation acceleratesContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by Investing.com as Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →